Introduction
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematopoietic stem cell disorder, related to a somatic mutation in the phosphatidylinositol glycan class A (PIG-A), X-linked gene, leading to deficient expression of glycosyl phosphatidylinositol-anchored proteins (GPI-APs). The disease is characterized by hemolytic anemia, marrow failure, or episodes of venous thrombosis events (TE).
The clinical pleiomorphic presentation of PNH has led to 2 recognize entities: one, predominantly hemolytic without overt marrow failure, is referred to as classical PNH 1 and the other, with marrow failure, is often described as the aplastic anemia -PNH syndrome (AA-PNH) 2 . Thromboses remain the major life-threatening complication in each disease subcategory 3, 4 .
Recent studies have focused on inhibiting the complement cascade, using
Eculizumab, a humanized anti-C5 monoclonal antibody in patients with hemolysis 5, 6 .
Eculizumab significantly reduces the risk of TE by inducing a significant and sustained decrease in the activation of both the plasma hemostatic system and the vascular endothelium 7 , likely contributing to its protective effect on the risk of thromboembolism 8 . Moreover, it has recently been suggested that Eculizumab improves survival 9 . Patients with severe aplastic anemia (SAA) with or without a PNH clone are currently treated with either allogeneic stem cell transplantation (SCT) or immunosuppressive therapy (IST) depending on patient age and on the availability of a suitable Human Leukocyte Antigen (HLA)-matched hematopoietic stem cell donor 10 .
The only curative treatment for PNH is SCT. In vitro and in vivo studies have
shown that PNH cells can be eradicated following SCT 11 . However, the risk for treatment-related mortality (TRM) after SCT is relatively high with graft-versus-host disease (GvHD) accounting for most of the TRM. There are limited number of singlecenter studies on SCT for PNH [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] (and reviewed in Parker  1 and Matos-Fernandez  22 ) and only one registry study involving more than 50 patients 23 . The decision to perform an SCT in PNH has usually been deferred until disease progression, to recurrent, life-threatening thromboembolism, refractory or transfusion-dependent hemolytic anemia, or development of SAA 1, 22 . 4 We evaluated the outcome and risk factors affecting survival after allogeneic SCT in the largest cohort ever studied of 211 PNH patients who were reported to the European Group for Blood and Marrow Transplantation (EBMT). Moreover, we conducted a formal survival comparison of this cohort of transplanted PNH patients with a matched cohort of non-transplanted PNH patients reported to, and previously published by, the French Society of Hematology (SFH) 3, 4 .
Design and methods

Data Collection
This retrospective multi-center study was conducted through the SAA Working Party Helsinki. EBMT registration requires informed consent by the patient, the SFH cohort has been approved by the review board of the SFH.
Statistical analysis
Transplanted PNH patients
Patient and SCT characteristics were described through proportions or median and inter-quartile range (IQR). Engraftment was defined as achieving an absolute neutrophil count of 0.5 x 10 9 /L for at least 3 consecutive days. Acute GvHD (aGvHD) and chronic GvHD (cGvHD) were defined and graded according to previous published criteria 26 . Cumulative incidence function (CIF), using death as a competing event, was used to estimate acute GVHD and chronic GvHD 27 . Concerning acute GvHD CIF, when the date of the event relatively to graft was unknown (26 patients), time to GvHD was randomly selected between 10 and 100 days using a uniform distribution. Survival was calculated from the date of transplantation to the date of last follow-up or date of death from any cause. The survival rates were calculated by the Kaplan-Meier method in the overall population and in the subgroups of patients according to SCT indication (TE, AA without TE) 28 . The following variables were tested as prognostic factors: age, sex matched between donor and recipient, interval from diagnosis to transplant, year of transplantation, stem cell source, donor type (sibling versus unrelated), indication for SCT (AA, recurrent hemolytic crisis or TE) and classification of the disease (classical PNH or AA-PNH). All factors were assessed separately using the Log-rank test and results expressed through hazards ratio (HR) with 95% confidence interval (CI) derived from the proportional hazard model 29, 30 . All factors with a p < 0.30 in the univariate analysis were analyzed in the multivariate model using proportional hazards regression. All models were built using backward selection and likelihood ratio test 30 . The same type of analysis was performed separately in patients grafted for TE and in those transplanted for AA without TE. Only factors that reached a P ≤ 0.05 were retained in the final model.
Survival comparison between transplanted and non-transplanted PNH patients
The comparison was performed from the time of a severe (life-threatening) complication occurring among patients who experienced the same type of complication, either TE or AA without TE. Among patients having experienced one of these complications, two matching procedures were used to select non-grafted patients comparable to grafted patients. First, a one to one matching procedure (matched pair analysis) was attempted using the a priori selected following criteria: severity of the complication, age at complication and year of complication, delay between PNH diagnosis and complication occurrence. In addition, the survival time from complication for a matched non-transplanted patient had to be longer than the time interval from the complication to SCT for the corresponding transplanted patient.
In a second step, a stratum matching procedure (global matching) was undertaken using the same prognostic factors to define strata related to survival in at least one of the 2 groups (grafted and non-grafted patients). Patients who developed myelodysplastic syndrome before AA or TE were excluded. Non-grafted patients who died within three months after a complication were also excluded, since they might have been considered scheduled for SCT but could not have received it.
For the one to one matching, severity of TE was defined in three classes: BuddChiari and/or central nervous system thrombosis, other thromboses except phlebitis, and phlebitis. Age at TE was matched at ± 10 years, year of TE at ± 15 years and time interval between TE and diagnosis on category defined as less than 1 month, 1 or 3 months, 3 to 6 months, 6 months or more. For aplastic anemia, 3 groups were defined; patients who did not receive immunosuppressive therapy, patients transplanted from HLA-identical siblings and patients who received an unrelated transplant for AA. Age at AA and year of AA were defined as for TE selection. The time interval between PNH and AA was defined as < 6 months, between 6 months before and 6 months after, and > 6 months after diagnosis. One to one matching of a non-grafted patient to a grafted patient was performed in order to select the maximum number of pairs in the analysis. The difference in overall survival (OS) between grafted and non-grafted patients was tested through proportional hazards model, stratified on each matched pair, and expressed as a hazard ratio with 95% confidence interval of grafted patients relative to non-grafted patients. In addition, OS was compared through proportional hazards model between selected and nonselected patients among grafted and non-grafted patients, separately to check that patients in the matched comparison did not differ from the total population.
For the stratum matching procedure, the following factors were tested: severity of complication, age at and year of complication per decade, delay between complication and PNH diagnosis defined in categories as for the one to one matching 7 procedure. The relation to survival was tested through proportional hazards model separately in each group. Starting from the most predictive survival factor, distribution of this factor across the 2 groups was examined and categories with no or very few patients (≤ 4) in one of the 2 groups were deleted. Then, the previous prognostic factors were searched for and the same procedure was applied to the successive predictive factors. At the end of this procedure, a combination of levels of the factors still related to survival in one of the 2 groups, defined a matching stratum for the survival comparison between the 2 groups. This comparison was first performed by using proportional hazards model stratified on strata, assuming that the hazard ratio among grafted patients relative to non-grafted patients did not vary across strata;
second, survival analysis was performed with the same proportional hazards model using as covariates, treatment, strata, interaction between treatment and strata, allowing us to test if hazard ratio among grafted patients relatively to non-grafted patients vary from one stratum to the other.
In all survival analysis using proportional hazards model, continuous factors were categorized using systematic limits defined approximately in quintiles (roughly 20 th , 40 th , 60 th and 80 th percentiles). If the relative death rates (ratio of the observed death rate in each category to the expected death rate, assuming no variation of death rate across categories) in two or more adjacent categories were not substantially different, these categories were combined. If no clear pattern was observed, the median value or usual limit was used as the cut-off point. As a consequence, 2 or rarely 3 categories were used for each continuous factor. The same approach was used in the survival analysis as a function of patient group (grafted or non-grafted), strata (as defined in the second step) and their interaction, leading in all cases to 2 or 3 different risk groups 31, 32 .
SPSS statistical software was used for all statistical analyses (Chicago, IL. USA).
Results
Patients' characteristics
A total of 211 patients from 83 centers, who underwent SCT for PNH between 1978
and 2007, were included in this study. The patients' characteristics are summarized in 4 and used for the matching analysis, are detailed in Table 2 . Of note none of the patients included in this non-transplanted cohort received Eculizumab.
Outcomes after Transplantation
Fourteen out of 202 documented patients did not engraft (7%). Eighty-five patients developed acute GvHD leading to a CIF of grade II-IV aGvHD of 40% (95%CI 34% -47%). Fifty-seven patients developed chronic GvHD (extensive, n=24) leading to a CIF of 29% (95%CI 23% -36%) at 5 years. Only one patient was documented with a PNH clone recurrence after SCT. After a median ± SE follow-up time of 61 months ± 6, 64 patients had died and the probability ± SE of OS was 68%±3% at 5 years ( Figure 1A ). As depicted in Supplementary Table 1 , infections and GvHD were the main causes of death. None of the variables investigated for an association with transplant outcome was a statistically significant predictor of survival (Table 3) were transplanted for TE (n=47) or for AA without TE (n=100) ( Table 3) . In multivariate analysis, no factor related to survival was identified in patients transplanted for TE. A long delay (>1 year between AA diagnosis and transplantation) ( Supplementary Fig 1A) Figure 4B) . We then identified factors associated with OS either in transplanted or in non-transplanted patients. Year of TE and age at TE were significantly associated with OS. We then selected patients with a date of TE after 1990 (there were very few patients in the transplanted group with a TE before this date) and who were less than 60 years old at TE (there were no patients in the transplanted group with 60 years of age or more at TE). After these selections (leading to 39 and 41 patients in the non-transplanted and transplanted groups, respectively) younger age at TE and shorter interval between PNH diagnosis and TE were significantly associated with better OS, leading to 2 prognostic strata: stratum A with (age <30 years and time interval ≥3 months, or time interval < 3 months) and stratum B (age ≥30 years and time interval years old, (there were no patient in the transplanted group more than 50 and 1 less than 10 years of age in the non-transplanted group). After these selections leading to 69 and 97 patients in the non-transplanted and transplanted groups, respectively, age at AA, date of AA and the time interval between PNH diagnosis and AA, were significantly associated with better OS, leading to too many strata (n=12). Further selection led to one or no deaths in the non-transplanted group. For these 2 reasons, the global matching was therefore not feasible for AA-PNH patients.
Discussion
In this large retrospective study, we described the characteristics and overall survival Fludarabine-based reduced intensity conditioning regimen showing no difference in terms of treatment related mortality or OS (data not shown). However, the retrospective setting of our study as well as the heterogeneity of the conditioning regimens precluded further analyses on the role of conditioning in the present series.
Acute and chronic GvHD occurred in roughly one third of our patients, which is not different to what has been reported in previous studies. With a median follow-up of 61 months, the OS is 68% corresponding to 32% of treatment related mortality.
Infectious complications are a major concern in our population representing the primary cause of mortality. This has been underestimated in previous smaller series, but is not unexpected considering the number of aplastic patients and the general susceptibility to infection in PNH 4 . The second cause of death was, as expected, GvHD 1 . One of the main findings of the present study is the demonstration of the strong impact of indication for transplantation on OS, especially the poor outcome of patients being transplanted for TE. More than one third of our patients were transplanted with unrelated donors and showed surprisingly an OS rate comparable to those transplanted with an HLA-identical sibling donor. Unrelated transplantation for AA has improved significantly over the past 15 years 37 , mainly due to a better HLA matching that may partly explain similar outcomes in the present study.
The most challenging question, however, is to identify those PNH patients who would benefit from SCT. To try to answer this question, we performed comparative analyses with matched cohorts of PNH patients who did or who did not receive a SCT. The main problem to be solved, when comparing two cohorts of patients receiving different treatments, is the comparability of the two cohorts for all criteria related to outcome. Comparability cannot be guaranteed in the absence of treatment allocation through randomization, a challenging task in the setting of an orphan disease.
Propensity score matching 38 could not be used here because both cohorts do have the same available data, but not at the same date (at diagnosis for non-transplanted patients, and at time of SCT for transplanted patients). Since the only factor related to OS was the indication for SCT in the transplanted group, and because the occurrence of a complication was the most important prognostic factor related to results but these patients were rare (n=16). In addition, we also found the importance of bone marrow as source of stem cells in this situation 42, 43 . While OS was not different between both sources of stem cells, a higher rate of chronic GvHD was observed in case of PBSC. Although this study reports the largest cohort of SCT for PNH and is quite unique in its aim to compare outcomes with non-transplanted patients, it has limitations inherent to retrospective analyses comparing different cohorts.
In conclusion, given our present results, and the efficacy of Eculizumab, the current indications for SCT should be challenged. SCT cannot be considered any longer as the standard of care of PNH patients with TE when eculizumab is available.
Regarding the good results of SCT in case of recurrent hemolytic crisis, SCT can be a valuable option for countries who cannot afford Eculizumab, regardless the type of donor. AA/PNH patients still seem to be appropriate candidates for SCT if they have severe disease. In the absence of an HLA-identical sibling donor, the current standard first line treatment for AA/PNH is IST.
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